NCT06607549 - Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (SOLAR) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2030

Conditions

Central Nervous System Lymphoma

Interventions

DRUG

Loncastuximab tesirine and rituximab (Lonca-R)

Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute at University of Utah, Salt Lake City